Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in ...

With the passage of the One Big Beautiful Bill Act, tax-exempt income remains untouched - a significant victory for investors ...

Hyundai has announced a range of updates for its 2026 models. Following record sales for the first half of the year, the Korean marque is taking nothing for granted, even shuffling trims and making ...